Abbott's $21B Exact Sciences Bet and AI-Powered Cath Lab Push Collide With a 30% Stock Drawdown

Abbott is shipping AI into the cardiac catheterization lab with Ultreon 3.0, dominating CGM with 56% global shipment share, and digesting a $21 billion cancer-screening acquisition — all while its stock trades at a decade-high dividend yield after a 30% selloff driven by nutrition weakness and EPS dilution.

ABT · Health Care · May 03, 2026

S&P 500 Position

Abbott sits in the Health Care Equipment & Supplies sub-industry alongside Medtronic, Edwards Lifesciences, and Stryker. Within the broader S&P 500 Health Care sector, it trails Johnson & Johnson, UnitedHealth, Eli Lilly, and AbbVie by market cap but leads all pure-play medical device companies. The Exact Sciences acquisition positions it more directly against Roche and Hologic in cancer screening diagnostics.

Index Weight: ~0.33% | Rank: Approximately 55–65 in S&P 500 by market cap

Company Overview

Abbott's center of gravity has shifted decisively toward Medical Devices, which now accounts for nearly half of total revenue and is pulling the rest of the company forward. The FreeStyle Libre franchise hit $2 billion in quarterly sales in Q1 2026, commanding 56% of global CGM shipments against Dexcom's 35%. Abbott's $10 billion CGM revenue target by 2028 rests on a penetration thesis: roughly 70–80 million people globally should be on continuous glucose monitors, but only 10–12 million currently are. The Lingo OTC biowearable extends the CGM platform beyond insulin-dependent diabetes into the wellness market for the first time. The March 2026 completion of the $21 billion Exact Sciences acquisition is the largest strategic move under CEO Robert Ford's tenure. It bolts Cologuard (colorectal cancer screening) and Cancerguard onto Abbott's diagnostics infrastructure, expected to contribute ~$3 billion in incremental 2026 revenue — though at a cost of $0.20/share in near-term EPS dilution and a $20 billion senior notes offering that meaningfully levered the balance sheet. Meanwhile, the cardiovascular pipeline is dense: Volt PFA and TactiFlex Duo catheters entered limited U.S. and European release in Q1, and H2 2026 trials are planned for a balloon-expandable TAVR valve, leadless conduction system pacing, mitral replacement, and peripheral intravascular lithotripsy. The company faces two material headwinds. Nutrition revenue fell 7.7% year-over-year in Q1 2026, and rapid/molecular diagnostics declined 10% on a weak respiratory testing season. More consequentially, Abbott confronts over 1,700 NEC lawsuits tied to Similac Special Care premature infant formula, with a $70 million jury verdict in April 2026 and Bloomberg Intelligence estimating total industry liability of up to $3 billion.

Products & Revenue

Abbott's revenue engine runs on four segments, but the story is increasingly one-sided. Medical Devices — spanning FreeStyle Libre CGMs, electrophysiology catheters, structural heart (MitraClip, TriClip, Navitor), and neuromodulation — grew 12.65% in FY2025 and now generates nearly half of all revenue. Diagnostics, once inflated by COVID testing, continues to normalize with core lab growing modestly while rapid/molecular testing declines. Nutritionals (Similac, Ensure, PediaSure) face both market softness and litigation risk. Established Pharmaceuticals, a branded generics business concentrated in emerging markets, is the steadiest grower outside devices. The Exact Sciences acquisition will meaningfully reshape the Diagnostics segment starting in FY2026.

Medical Devices (48.3%): FreeStyle Libre CGMs, electrophysiology mapping and ablation catheters (including PFA), structural heart devices (MitraClip, TriClip, Navitor TAVI), coronary imaging (OCT/Ultreon), neuromodulation, and vascular closure. Double-digit growth in EP and heart failure in Q1 2026.

Diagnostic Products (20.2%): Core laboratory immunoassay and clinical chemistry platforms (Alinity, ARCHITECT), point-of-care testing (i-STAT), rapid diagnostics (BinaxNOW), and molecular platforms. Now includes Exact Sciences' Cologuard and Cancerguard cancer screening assets post-acquisition.

Nutritional Products (19.1%): Pediatric nutrition (Similac, PediaSure), adult nutrition (Ensure, Glucerna). Revenue declined 7.7% YoY in Q1 2026 amid competitive pressure and NEC litigation overhang.

Established Pharmaceutical Products (12.5%): Branded generic pharmaceuticals sold primarily in emerging markets (India, China, Brazil, Russia). Grew to $5.54B in FY2025, benefiting from volume expansion in key therapeutic areas.

Segment percentages based on FY2025 annual revenue ($44.32B) per Bullfincher/Abbott filings. TTM revenue of $45.13B through March 31, 2026 includes partial Exact Sciences contribution.

Leadership

Robert B. Ford

CEO since 2020. Ford was appointed President & CEO in March 2020 and Chairman in December 2021. He joined Abbott in 1996 and rose through the devices business, overseeing the FreeStyle Libre global launch. His strategic priorities center on CGM expansion, AI-powered devices, and large-scale M&A — the Exact Sciences deal being the clearest expression of his willingness to make transformative bets. Total compensation: $22.78M, 93.4% performance-based.

Phil Boudreau, EVP Finance & CFO: Architect of the $20 billion bond offering that funded the Exact Sciences acquisition. Manages the integration's financial impact while guiding the market through the $0.20/share EPS dilution.

Sabina Ewing, SVP Business & Technology Services / CIO: Elevated to the executive suite as part of Abbott's accelerated AI agenda post-JPM 2024. Oversees AI infrastructure strategy across all four business segments.

Eric S. Fain, M.D., SVP & Group President, Cardiovascular & Neuromodulation: Runs Abbott's highest-growth division. Responsible for the Ultreon 3.0 rollout, Volt PFA catheter launch, TriClip scaling, and upcoming TAVR and leadless pacing trials.

Jared L. Watkin, SVP Diabetes Care: Leads the FreeStyle Libre franchise targeting $10B in annual CGM revenue by 2028. Oversees the Lingo OTC expansion and dual-analyte (glucose + ketone) sensor development.

John M. Capek, Ph.D., EVP Ventures: Runs Abbott's venture and early-stage technology arm. Drove the Laralab acquisition in October 2025, sourcing AI-based cardiac imaging technology for integration into interventional cardiology.

The AI Angle

AI enters the cath lab via coronary imaging

Abbott's AI strategy is tightly scoped: deploy machine learning inside procedural medical devices where real-time image interpretation directly affects clinical outcomes. The flagship product is Ultreon 3.0, cleared by the FDA and CE-marked on April 28, 2026. It is the first OCT system in the U.S. and Europe to integrate high-resolution coronary plaque imaging with AI-automated clinical insights. The system performs a one-second infrared pullback of a coronary artery, then runs AI algorithms that assess plaque type (lipid, calcified, fibrous), recommend optimal stent size and placement, and confirm post-procedure blood flow — all during a live PCI procedure. The addressable surface is large: over 600,000 PCI procedures are performed annually in the U.S. alone, and OCT offers higher resolution than competing intravascular ultrasound (IVUS) with low or zero contrast agent. Abbott's AI build-versus-buy calculus leans toward targeted acquisitions fed into existing device platforms. In October 2025, Abbott acquired Laralab, a German AI cardiac imaging startup, and is integrating its pre-procedure planning algorithms into interventional cardiology workflows. This is the same playbook Abbott used to build the Ultreon line: acquire specialized computer vision capabilities, then embed them into hardware systems that already have regulatory pathways and installed bases in hospitals. Organizationally, CEO Robert Ford signaled AI as a growth pillar at the January 2024 J.P. Morgan Healthcare Conference, and shortly afterward elevated CIO Sabina Ewing to the executive suite to lead the cross-segment AI infrastructure push. The move was more than cosmetic — it placed technology architecture decisions at the same table as segment presidents, which matters when AI inference needs to run on edge devices inside catheterization labs and on FreeStyle Libre sensor platforms. The competitive risk is real but manageable. In coronary imaging, Philips (IVUS) and Boston Scientific are the primary competitors, but neither has shipped an FDA-cleared AI-integrated OCT system. In CGM, Dexcom is investing in its own AI-driven insulin dosing algorithms. Abbott's moat here is the combination of sensor hardware dominance (56% CGM shipment share) with a growing software layer — the dual-analyte CGM (glucose + ketone) expected in H2 2026 will add another data channel for algorithmic coaching. The risk is that Abbott's AI remains narrow and procedural; it is not building foundation models or general-purpose platforms. That narrowness is also its strength: every AI feature ships inside a regulated device with a clear reimbursement pathway.

Financial Snapshot

Revenue (TTM): $45.1B — TTM ending March 31, 2026 | Net Income: $6.3B net income (TTM)

Margins: Net margin 13.9%; data unavailable for gross and operating margins from provided sources

TTM revenue of $45.1B reflects 6.6% year-over-year growth, partially boosted by partial Exact Sciences consolidation. Abbott cut full-year 2026 adjusted EPS guidance to $5.38–$5.58 from $5.55–$5.80, reflecting $0.20 of Exact Sciences dilution. The stock dropped ~5% on the revision. Capital allocation is now tilted toward debt service and integration; the 54-year dividend streak ($2.52/share annually, ~2.8% yield) remains intact but share buybacks will likely be muted until leverage normalizes.

1-Year Performance

$89.46 as of May 3, 2026. The stock is down approximately 30% over the past year.

The drawdown reflects three converging pressures: nutrition segment weakness (-7.7% Q1 YoY), rapid diagnostics decline on a weak respiratory season, and the EPS dilution from the Exact Sciences acquisition. The resulting ~2.8% dividend yield is the highest Abbott has offered in a decade. Investors are effectively being asked to underwrite the $10B CGM growth thesis and the Exact Sciences integration against near-term margin compression and NEC litigation tail risk.

Recent News

Fun Fact: Abbott's OCT (optical coherence tomography) imaging platform — the foundation for Ultreon 3.0 — traces its technical lineage to a 2017 acquisition of St. Jude Medical, which itself had acquired the technology from LightLab Imaging. The core technique was originally developed at MIT's Lincoln Laboratory for telecommunications fiber optic testing in the early 1990s before being adapted for medical imaging. Abbott now uses it to generate cross-sectional artery images at resolutions of approximately 10–15 micrometers — roughly ten times sharper than intravascular ultrasound — by measuring the echo time delay of near-infrared light reflected from tissue.